Evolution of Treatment for Diabetic Nephropathy: Historical Progression From RAAS Inhibition and Onward

被引:9
作者
Blumenthal, Samuel S. [1 ]
机构
[1] Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA
关键词
type 2 diabetes mellitus; diabetic nephropathy; diabetic kidney disease; renal disease; HEPATOCYTE GROWTH-FACTOR; GLYCATION END-PRODUCTS; BLOOD-PRESSURE CONTROL; DIETARY-PROTEIN RESTRICTION; CORONARY-ARTERY-DISEASE; MATRIX GENE-EXPRESSION; CHRONIC RENAL-DISEASE; FACTOR-BETA; CARDIOVASCULAR OUTCOMES; KIDNEY-FUNCTION;
D O I
10.3810/pgm.2011.11.2506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The past 2 decades have brought rapid advances in treatment options for chronic kidney disease; however, even with the best treatment, the decline of renal function and progression to end-stage renal disease (ESRD) continues in a significant number of patients. The prognosis of patients with diabetes and ESRD is grim, with < 50% of patients surviving beyond 5 years after diagnosis. Therefore, early recognition and optimal use of available interventions are essential, and research into newer therapeutic targets is needed. This article will review recent advances in our understanding of renal pathophysiology, summarize the evidence to date supporting current treatment options for diabetic nephropathy, and highlight new options that lie on the horizon for the treatment of diabetic kidney disease.
引用
收藏
页码:166 / 179
页数:14
相关论文
共 114 条
  • [91] Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
    Sharma, K
    Jin, YL
    Guo, J
    Ziyadeh, FN
    [J]. DIABETES, 1996, 45 (04) : 522 - 530
  • [92] Increased renal production of transforming growth factor-beta(1) in patients with type II diabetes
    Sharma, K
    Ziyadeh, FN
    Alzahabi, B
    McGowan, TA
    Kapoor, S
    Kurnik, BRC
    Kurnik, PB
    Weisberg, LS
    [J]. DIABETES, 1997, 46 (05) : 854 - 859
  • [93] The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy
    Shimoike, T
    Inoguchi, T
    Umeda, F
    Nawata, H
    Kawano, K
    Ochi, H
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (08): : 1030 - 1035
  • [94] Sogno I, 2009, RECENT RESULTS CANC, V181, P209
  • [95] SOULISLIPAROTA T, 1995, DIABETOLOGIA, V38, P387, DOI 10.1007/BF00410275
  • [96] MESANGIAL EXPANSION AS A CENTRAL MECHANISM FOR LOSS OF KIDNEY-FUNCTION IN DIABETIC-PATIENTS
    STEFFES, MW
    OSTERBY, R
    CHAVERS, B
    MAUER, SM
    [J]. DIABETES, 1989, 38 (09) : 1077 - 1081
  • [97] Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    Stratton, IM
    Adler, AI
    Neil, HAW
    Matthews, DR
    Manley, SE
    Cull, CA
    Hadden, D
    Turner, RC
    Holman, RR
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258): : 405 - 412
  • [98] The Diabetes Control and Complications Trial Research Group, N Engl I Med. I, V993, P977
  • [99] Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
    Thornalley, PJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) : 31 - 40
  • [100] Potential New Therapeutic Agents for Diabetic Kidney Disease
    Turgut, Faruk
    Bolton, Warren Kline
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (05) : 928 - 940